《肿瘤瞭望》：一针定乾坤？
Neulasta Onpro: a coup de grâce?
机构信息
Division of Supply Chain Management, Mayo Clinic, 200 1st St SW, Rochester, MN 55905. Email:
出版信息
Am J Manag Care. 2023 Mar 1;29(3):e69-e70. doi: 10.37765/ajmc.2023.89331.
PMID:36947018
Abstract
With the rapid decline in average sales price of reference pegfilgrastim products due to biosimilar competition, health care institutions and payers may grapple with coverage of Neulasta Onpro.
摘要
由于生物类似药的竞争，参照性聚乙二醇化非格司亭产品的平均销售价格迅速下降，医疗机构和支付方可能会面临 Neulasta Onpro 的覆盖问题。
Zotero 插件